Biotech

All Articles

More collaborative FDA can accelerate uncommon illness R&ampD: file

.The FDA should be actually extra available and joint to unleash a surge in commendations of unusual...

Zenas, MBX, Bicara head to Nasdaq in scorching time for biotech IPOs

.It's an uncommonly hectic Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara Therapeutic...

Atea's COVID antiviral fails to halt hospital stays in phase 3

.Atea Pharmaceuticals' antiviral has stopped working yet another COVID-19 trial, yet the biotech sti...

Neurocrine's bid to conserve mental illness possibility falls short

.Neurocrine Biosciences' schizophrenia system pivot has actually neglected. The biotech was actually...

Sanofi pays out $110M upfront for late-stage radioligand therapy

.Sanofi has actually made a late access to the radioligand gathering, paying for 100 million europea...

F 2G rears $100M for 2nd attempt to get brand new antifungal to market

.After F2G's initial attempt to receive a brand-new lesson of antifungal to market was wrecked by th...

Moderna targets $1.1 B in R&ampD spending slices, drops 5 systems among profitability tensions

.Moderna has vowed to cut R&ampD spending by $1.1 billion by 2027. The selection to shrink the budge...

Sanofi's $80M bet on Pivot dystrophy drug ends in phase 3 go belly up

.Just 4 months after Sanofi wager $80 million in upfront cash money on Key Rehabs' losmapimod, the c...

Oncternal assets drains 60% amidst discharges, test firings

.Cancer firm Oncternal Rehabs is folding all its own clinical tests and also giving up workers, swit...

Roche is carrying out chances that its injectable obesity possibility might ultimately display 25% fat burning in late-stage test

.Roche is keeping out chances that its injectable excessive weight possibility can at some point dem...